Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma.

Medullary thyroid carcinoma (MTC) is a rare endocrine tumor that frequently metastasizes, but treatment with irinotecan (CPT-11) is limited because of side effects. MTC is known to overexpress the somatostatin receptor subtype 2 (SSTR2). Octreotide (Oct) is a somatostatin analogue that has a high binding affinity for SSTR and can be used as a tumor-targeting ligand. We prepared Oct-targeted liposomes loaded with CPT-11 using Oct-poly (ethylene glycol) (PEG)-lipid and evaluated Oct-mediated association and cytotoxicity of the liposomes with an MTC cell line TT. The association of higher concentrations of modified Oct-targeted liposomes with TT cells was significantly higher than PEGylated liposomes and was significantly inhibited by empty Oct-targeted liposomes but not by free Oct. With exposure for 96 h, the cytotoxicity of Oct-targeted liposomal CPT-11 (IC50: 1.05 ± 0.47 μM) was higher than free CPT-11 (IC50: 3.76 ± 0.61 μM) or PEGylated liposomal CPT-11 (IC50: 3.05 ± 0.28 μM). In addition, empty Oct-targeted liposomes showed significantly higher cytotoxicity than empty nontargeted liposomes at a concentration where free Oct did not show cytotoxicity, suggesting that Oct as a ligand showed cytotoxicity. Moreover, Oct-targeted liposomal CPT-11 led to significantly higher antitumor activity and prolonged the survival time compared with nontargeted liposomal and free CPT-11 at a one-third dose and lower administration times with free CPT-11. These findings indicated that Oct-targeted liposomes loaded with CPT-11 may offer considerable potential for MTC chemotherapy because cytotoxicity of both CPT-11 and Oct was enhanced by effective cellular uptake via SSTR2.

[1]  Y. Maitani,et al.  Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis , 2010, Cancer science.

[2]  A. Grossman,et al.  Medullary Thyroid Cancer: Molecular Biology and Novel Molecular Therapies , 2009, Neuroendocrinology.

[3]  Li Shi,et al.  Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[4]  T. Honda,et al.  Design of Folate-Linked Liposomal Doxorubicin to its Antitumor Effect in Mice , 2008, Clinical Cancer Research.

[5]  Yu-Chih Liang,et al.  Liposome encapsulation reduces cantharidin toxicity. , 2008, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[6]  M. Korbonits,et al.  Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. , 2008, Endocrine-related cancer.

[7]  Shih-Kwang Wu,et al.  A synthetic method for peptide-PEG-lipid conjugates: application of octreotide-PEG-DSPE synthesis. , 2008, Bioorganic & medicinal chemistry letters.

[8]  H. Fang,et al.  Evaluation of Multi-Target and Single-Target Liposomal Drugs for the Treatment of Gastric Cancer , 2008, Bioscience, biotechnology, and biochemistry.

[9]  Hiroaki Arai,et al.  Bootstrap re-sampling technique to evaluate the optimal formulation of theophylline tablets predicted by non-linear response surface method incorporating multivariate spline interpolation. , 2007, Chemical & pharmaceutical bulletin.

[10]  U. Pagotto,et al.  Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. , 2006, Cancer research.

[11]  Y. Hsiang,et al.  Intracellular Target of the Anticancer Drug Camptothecin Identification of Mammalian DNA Topoisomerase I as an Updated , 2006 .

[12]  C. Strock,et al.  Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. , 2006, The Journal of clinical endocrinology and metabolism.

[13]  P. Courtoy,et al.  Endocytosis of the somatostatin analogue, octreotide, by the proximal tubule-derived opossum kidney (OK) cell line. , 2005, Kidney international.

[14]  Samuel Zalipsky,et al.  Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. , 2004, Advanced drug delivery reviews.

[15]  H. Yanagie,et al.  Liposomes Bearing Polyethyleneglycol-Coupled Transferrin with Intracellular Targeting Property to the Solid Tumors In Vivo , 2001, Pharmaceutical Research.

[16]  Kensuke Matsumoto,et al.  Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice , 2004, Cancer Chemotherapy and Pharmacology.

[17]  J. Taylor,et al.  Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT. , 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[18]  A. Eberle,et al.  Somatostatin analogs and radiopeptides in cancer therapy. , 2002, Biopolymers.

[19]  A. Abbruzzese,et al.  Current approaches and perspectives in the therapy of medullary thyroid carcinoma , 2001, Cancer.

[20]  J. Taylor,et al.  Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. , 2001, The Journal of clinical endocrinology and metabolism.

[21]  A. Beaudet,et al.  Receptor‐mediated internalization of somatostatin in rat cortical and hippocampal neurons , 2000, Synapse.

[22]  C. M. Huang,et al.  Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis. , 2000, Chemistry & biology.

[23]  C. Beglinger,et al.  Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. , 2000, Endocrinology.

[24]  H. Gharib,et al.  Current diagnosis and management of medullary thyroid carcinoma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  A. de Leiva,et al.  Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. , 1998, The Journal of clinical endocrinology and metabolism.

[26]  P. Smith-Jones,et al.  Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours. , 1998, Nuclear medicine and biology.

[27]  G. Vitale,et al.  Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon α‐2b and octreotide , 1996, Cancer.

[28]  A. Tabarin,et al.  Results of long‐term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma , 1992, Clinical endocrinology.

[29]  H. Kuga,et al.  Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. , 1991, Cancer research.

[30]  T. Visser,et al.  In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  R. Ohno,et al.  An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Azria,et al.  Disposition of sandostatin, a new synthetic somatostatin analogue, in rats. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[33]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[34]  L. Liu,et al.  Topoisomerases: novel therapeutic targets in cancer chemotherapy. , 1988, Biochemical pharmacology.

[35]  J. Rosenthaler,et al.  Pharmacokinetics of SMS 201-995 in healthy subjects. , 1986, Scandinavian journal of gastroenterology. Supplement.

[36]  L. Gráf,et al.  Demonstration by immunofluorescence of the lipotropic hormone-LPH in bovine, ovine and procine adenohypophysis. , 1973, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.